Dr. Reddy's launches Dimethyl Fumarate Delayed-Release Capsules in US market

28 Sep 2020 Evaluate

Dr. Reddy’s Laboratories has launched Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfidera (dimethyl fumarate) Delayed-Release Capsules, approved by the U.S. Food and Drug Administration (USFDA).

The Tecfidera brand and generic market had U.S. sales of approximately $3.8 billion MAT for the most recent twelve months ending in June 2020, according to IQVIA Health. The company’s Dimethyl Fumarate Delayed-Release Capsules are available in 120 mg and 240 mg capsules in bottle count sizes of 14 and 60 capsules, respectively.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1208.55 -15.75 (-1.29%)
29-Jan-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1589.30
Dr. Reddys Lab 1208.55
Cipla 1320.35
Zydus Lifesciences 890.20
Lupin 2122.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×